Skip to main content
Top
Published in: Annals of Hematology 3/2022

01-03-2022 | Splenectomy | Original Article

First report of successful treatment for hemoglobin Bristol-Alesha by hemopoietic stem cell transplantation

Authors: Shanshan Li, Kai Chen, Can Huang, Na Zhang, Hui Jiang, Shayi Jiang

Published in: Annals of Hematology | Issue 3/2022

Login to get access

Abstract

HBB gene mutations lead to many kinds of diseases, of which, except for the two most common diseases of thalassemia and sickle cell anemia, rare kinds of hemolytic anemia, such as hemoglobin Bristol-Alesha, are rarely reported, no ideal treatment in clinic. A child suffered from chronic recurrent hemolytic attacks and the related genes of hereditary hemolytic anemia were detected on her. Hematopoietic stem cell transplantation was conducted in the treatment of the patient. The patient was diagnosed as hemoglobin Bristol-Alesha and achieved complete recovery after hematopoietic stem cell transplantation. For Bristol-Alesha, without characteristic clinical manifestation and specific biochemical examination, diagnosis is dependent on the gene mutation detection and hematopoietic stem cell transplantation is an effective and curable method.
Literature
1.
go back to reference Alonso L, González-Vicent M, Belendez C et al (2019) Haematopoietic stem cell transplantation in paediatric patients with thalassaemia and sickle cell disease: An experience of the Spanish Working Group for Bone Marrow Transplantation in Children (GETMON). Med Clin (Barc) 152(4):135–140CrossRef Alonso L, González-Vicent M, Belendez C et al (2019) Haematopoietic stem cell transplantation in paediatric patients with thalassaemia and sickle cell disease: An experience of the Spanish Working Group for Bone Marrow Transplantation in Children (GETMON). Med Clin (Barc) 152(4):135–140CrossRef
2.
go back to reference Bernaudin F, Pondarré C, Galambrun C et al (2017) Allogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia. Adv Exp Med Biol 1013:89–122CrossRef Bernaudin F, Pondarré C, Galambrun C et al (2017) Allogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia. Adv Exp Med Biol 1013:89–122CrossRef
3.
go back to reference Brockmann K, Stolpe S, Fels C et al (2005) Moyamoya Syndrome Associated With Hemolytic Anemia Due to Hb Alesha. J Pediatr Hematol Oncol 27(8):436–440CrossRef Brockmann K, Stolpe S, Fels C et al (2005) Moyamoya Syndrome Associated With Hemolytic Anemia Due to Hb Alesha. J Pediatr Hematol Oncol 27(8):436–440CrossRef
4.
go back to reference Eberle SE, Noguera NI, Sciuccati G et al (2007) Hb Alesha [beta67(E11) Val–>Met, GTG–>ATG] in an Argentinean girl. Hemoglobin 31(3):379–382CrossRef Eberle SE, Noguera NI, Sciuccati G et al (2007) Hb Alesha [beta67(E11) Val–>Met, GTG–>ATG] in an Argentinean girl. Hemoglobin 31(3):379–382CrossRef
5.
go back to reference Englum BR, Rothman J, Leonard S et al (2016) Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia 51(1):122–127 Englum BR, Rothman J, Leonard S et al (2016) Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia 51(1):122–127
6.
go back to reference Haley K (2017) Congenital Hemolytic Anemia. Med Clin North Am 101(2):361–374CrossRef Haley K (2017) Congenital Hemolytic Anemia. Med Clin North Am 101(2):361–374CrossRef
7.
go back to reference Jiang H, Yan JM, Zhou JY, et al (2016) Hb Alesha [β67(E11) Val→Met (GTG>ATG); HBB: c.202G > A] Found in a Chinese Girl. Hemoglobin 40(6): 420–421. Jiang H, Yan JM, Zhou JY, et al (2016) Hb Alesha [β67(E11) Val→Met (GTG>ATG); HBB: c.202G > A] Found in a Chinese Girl. Hemoglobin 40(6): 420–421.
8.
go back to reference Pedroso GA, Kimura EM, Santos MNN, et al (2017) Coinheritance of Hb Bristol-Alesha [β67(E11)Val→Met; HBB: c.202G>A] and the α212 Patchwork Allele in a Brazilian Child with Severe Congenital Hemolytic Anemia. Hemoglobin 41(3): 203–208. Pedroso GA, Kimura EM, Santos MNN, et al (2017) Coinheritance of Hb Bristol-Alesha [β67(E11)Val→Met; HBB: c.202G>A] and the α212 Patchwork Allele in a Brazilian Child with Severe Congenital Hemolytic Anemia. Hemoglobin 41(3): 203–208.
9.
go back to reference Rees DC, Rochette J, Schofield C et al (1996) A novel silent posttranslational mechanism converts methionine to aspartate in hemoglobin Bristol (beta 67[E11] Val-Met->Asp). Blood 88(1):341–348CrossRef Rees DC, Rochette J, Schofield C et al (1996) A novel silent posttranslational mechanism converts methionine to aspartate in hemoglobin Bristol (beta 67[E11] Val-Met->Asp). Blood 88(1):341–348CrossRef
10.
go back to reference Thom CS, Dickson CF, Gell DA et al (2013) Hemoglobin variants: biochemical properties and clinical correlates. Cold Spring Harb Perspect Med 3(3):a011858CrossRef Thom CS, Dickson CF, Gell DA et al (2013) Hemoglobin variants: biochemical properties and clinical correlates. Cold Spring Harb Perspect Med 3(3):a011858CrossRef
Metadata
Title
First report of successful treatment for hemoglobin Bristol-Alesha by hemopoietic stem cell transplantation
Authors
Shanshan Li
Kai Chen
Can Huang
Na Zhang
Hui Jiang
Shayi Jiang
Publication date
01-03-2022
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 3/2022
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-021-04721-7

Other articles of this Issue 3/2022

Annals of Hematology 3/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine